latest news releases from the newsroom
Antisoma in-licenses telomerase inhibitor programme from Cancer Research Technology
LONDON, Sept. 10, 2003 (PRIMEZONE) -- Antisoma plc, (LSE:ASM) (NASDAQ Europe:ASOM) (Other OTC:AIOAF) the biopharmaceutical company specialising in novel anti-cancer drugs, today announces that it has in-licensed a programme of telomerase inhibitors from Cancer Research Technology Ltd, the technology transfer arm of the charity Cancer Research UK. This programme was developed by Professor Stephen Neidle, working first at the Institute of Cancer Research and more recently at the University of London School of Pharmacy. Under the licensing agreement, Antisoma has obtained rights to a number of existing molecules and an option on further telomerase inhibitors generated by Professor Neidle's group over the next three years.
The Pomerantz Firm Charges Quest Software with Securities Fraud -- QSFT
NEW YORK, Sept. 9, 2003 (PRIMEZONE) -- Pomerantz Haudek Block Grossman & Gross LLP (www.pomerantzlaw.com) has filed a class action lawsuit against Quest Software, Inc.("Quest" or the "Company") (Nasdaq:QSFT) and five of the Company's senior officers and directors on behalf of investors who purchased the common stock of Quest during the period between April 30, 2002 and July 23, 2003, inclusive (the "Class Period").